Role Of Cisplatin And Cyclophosphamide Chemotherapy In Bulky Residual Disease After Primary Cytoreductive Surgery Of Epithelial Ovarian Cancers.
DOI:
https://doi.org/10.21649/akemu.v4i1.3762Keywords:
Cytoreduction surgery, chemotherapy, and ovarian tumour.Abstract
From May 1993 to June 1997, 58 patients with bulky residual disease after primary cytoreductive surgery of epithelial ovarian cancer were treated with cisplatin and cyclophosphamide combination chemotherapy. Overall responses were seen in 30 patients (51.72%) with complete responses in 9 patients (15.51%) and partial responses in 21 patients (36.11%) at 4 months. 28 patients (48.27%) were non-responders. Response in relation to the size of residual disease revealed that 24 out of 36 patients (66.66%) did not show a complete response to chemotherapy. It is concluded that bulky residual disease of greater than 4 cm responds poorly to cisplatin and cyclophosphamide combination chemotherapy.Downloads
Published
08/11/2020
How to Cite
., S., ALAUDDIN, Z. ., FARUQUI, Z. ., HUSSAIN, M. ., MANZOOR, N. ., RASOOL, Z. ., & HUSSAIN, A. J. . (2020). Role Of Cisplatin And Cyclophosphamide Chemotherapy In Bulky Residual Disease After Primary Cytoreductive Surgery Of Epithelial Ovarian Cancers. Annals of King Edward Medical University, 4(1), 13–15. https://doi.org/10.21649/akemu.v4i1.3762
Issue
Section
Research Articles
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments publications@kemu.edu.pk